Merck (MRK) stock trended lower as Halozyme (HALO) challenges the company over injectable Keytruda patents. Read more here.

HC Wainwright reiterated their buy rating on shares of Halozyme Therapeutics (NASDAQ:HALO – Free Report) in a report published on Thursday,Benzinga reports. Several other equities analysts have also ...

Both Merck & Co. and Halozyme are holding their ground in a freshly unveiled patent dispute surrounding the New Jersey pharma ...

Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Dr. Helen Torley, president and chief executive ...

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

The new formulation of Keytruda, currently under FDA review, is sparking conflict with Halozyme, which makes enzymes that ...

Piper Sandler analyst Joseph Catanzaro maintained a Hold rating on Halozyme (HALO – Research Report) today and set a price target of $53.00.

Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO – Get Free Report) have been given an average rating of “Moderate Buy” by the ten analysts that are presently covering the company, Ratings reports.

Merck's injected version of its blockbuster cancer drug Keytruda could face a potential patent challenge from biotech ...

Merck (MRK) has been adjusting Keytruda to make it easier to use and to protect the company for after the U.S. patent protection runs out in ...

Halozyme Therapeutics claims Merck's new Keytruda version infringes on patents, requiring a licensing agreement, reports WSJ.